KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biogen (BIIB) Income from Continuing Operations (2016 - 2026)

Biogen has reported Income from Continuing Operations over the past 18 years, most recently at 319500000.0 for Q1 2026.

  • For Q1 2026, Income from Continuing Operations rose 32.85% year-over-year to 319500000.0; the TTM value through Mar 2026 reached 1371900000.0, down 7.26%, while the annual FY2025 figure was 1292900000.0, 20.79% down from the prior year.
  • Income from Continuing Operations for Q1 2026 was 319500000.0 at Biogen, up from 48900000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 1134900000.0 in Q3 2022 and troughed at 68300000.0 in Q3 2023.
  • A 5-year average of 433241176.47 and a median of 388500000.0 in 2024 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: surged 1538.48% in 2022 and later tumbled 118.34% in 2025.
  • Year by year, Income from Continuing Operations stood at 549500000.0 in 2022, then plummeted by 54.7% to 248900000.0 in 2023, then grew by 7.15% to 266700000.0 in 2024, then tumbled by 118.34% to 48900000.0 in 2025, then skyrocketed by 753.37% to 319500000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for BIIB at 319500000.0 in Q1 2026, 48900000.0 in Q4 2025, and 466500000.0 in Q3 2025.